Posted by Michael Wonder on 10 Mar 2021
AVEO Oncology announces U.S. FDA approval of Fotivda (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma
10 March 2021 - AVEO plans to make Fotivda available to patients in the U.S. by 31 March 2021.
AVEO Oncology today announced that the U.S. FDA has approved Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.
